Democritus University of Thrace (DUTH)
Ραδιοβιολογική ανάλυση του σχεδιασμού ακτινοθεραπείας σε ασθενείς με καρκίνο προστάτη που υποβάλλονται σε υποκλασματοποιημένη και επιταχυνόμενη VMAT ακτινοθεραπεία
Abstract
dc:descriptionProstate cancer is the second most commonly diagnosed cancer in men and the fifth leading cause of death in 2020. The estimated new cases reach 1.4 million, while the estimated number of deaths reaches 375 thousand, worldwide for the same year. Although the cause of the disease is unknown, diet related factors and smoking may increase the risk to develop prostate cancer.The main treatments for this disease are Surgery, Radiation Therapy, Hormone Therapy and Chemotherapy, either in combination or separately. Additional treatment methods are Immunotherapy, Targeted agents etc.External Beam Radiotherapy uses Linear Accelerators, which deliver high-energy X-rays to the patient's area of interest, with the aim of killing the cancer cells or preventing them from growing. 3D Conformal Radiotherapy (3D-CRT), Intensity Modulated Radiation Therapy (IMRT) and Volumetric Arc Therapy (VMAT) are advanced radiotherapy techniques used to deliver high doses of radiation to the tumor while minimizing damage to surrounding healthy tissues.The administration of the total dose to the tumor is performed in fractions (sessions) and its fragmentation or division into smaller dose portions is called fractionation of the total dose. The total dose and fractionation to be used determine the biological effect of a radiation. In clinical practice, the administration of 2 Gy (1.8-2.2 Gy) fractions, daily, five days per week is called conventional fractionation (Conventional Radiotherapy, CRT). The administration of smaller fractions (<1.8 Gy) twice daily, is called Hyperfractionated Radiotherapy (HyperRT) and radiotherapy regimens, in which the dose per fraction is greater than 2.2 Gy are called Hypofractionated and Acceletated Radiotherapy (HypoAR).The Linear Quadratic Model (LQ model) is an effective tool for understanding the responses of cancer and normal cells to radiation in clinical practice and provides the best description of the radiation response at low doses. According to this model, Macejewsky introduced the concept of Normalized Total Dose (NTD) in order to translate any fractionation and treatment acceleration to an equivalent dose that would have been delivered with conventional fractionation (2 Gy/day). Therefore, to obtain the NTD (α/β) for an arbitrary ‘n’ fraction of the ‘d’ dose fraction, we find the dose that yields the same effect:αNTD∙(1+2/(α⁄β))=αD∙(1+d/(α⁄β))Solving in terms of NTD we have:NTD(α⁄β)=D∙((d+α⁄β)/(2+α⁄β)) (1) Where, D: is the total administered dose of the alternative fractionation and d: is the dose per fraction.In different duration of Radiotherapy regimens, the reduction in time should be considered in terms of early toxicities, as early effects depend on the stem cells or the proliferation and the tumor cells clonality. Therefore equation (4), taking into account the acceleration from the reduction of the treatment time takes the form:NTD_Τ(α⁄β)=D∙((d+α⁄β)/(2+α⁄β))+λ∙(T_c-T_o) (2) Where: λ: is the estimated daily dose consumed to compensate for rapid tumor repopulation, Tc: is the number of days required to administer NTD by standard fractionation and To: is the number of days required to administer of the accelerating scheme.Hypofractionated Radiotherapy is divided into two distinct categories: moderate hypofractionation, defined as 2.4-3.4 Gy per fraction, and ultra-HypoAR, defined as at least 5-8 Gy per fraction. The Department of Radiotherapy Oncology of the University General Hospital of Alexandroupolis for many years has been providing hypofractionated and accelerated radiotherapy regimens in most anatomical sites.The adoption of hypofractionated radiotherapy during the last decade has significantly altered the clinical practice of Radiotherapy for many human tumors. This led to a reduction of the overall treatment time, reduction of the cost of radiotherapy and, eventually, to an increase of the efficacy keeping toxicities at low levels. The purpose of the current PhD is the radiobiological analysis of three clinical Radiotherapy schemes used in clinical practice, in patients with low-risk, high-risk prostate cancer and in patients who have undergone radical prostatectomy, respectively.Based on the above, the study focused on the following directions:Processing of Dose-Volume Histograms (DVH) data of the hypofractionated schemes and creation of the biological b-DVHs.Creation of new treatment plans using standard fractionation with prescription doses, the doses calculated from equations (1) and (2) for each fractionated regimen.Processing of DVH data of conventional fractionated schemes and creation of biological b-DVHs.Comparative and statistical analysis of the above data in terms of early and late toxicities.Clinical evaluation of the results and investigation of the advantages and disadvantages of the ultra-HypoAR and HypoAR radiotherapy regimens, compared to the CRT regimens, respectively.In conclusion, our clinical experience with ultra-HypoAR and HypoAR regimens in prostate cancer patients, whether it concerns local prostate or pelvic lymph nodes irradiation, is encouraging. The low profile of early and late toxicity recorded for each scheme, make them safe and effective. In addition, they reduce the duration of treatment and are more attractive to patients who need to travel to Radiotherapy Departments from remote cities and villages. Finally, the reduction to 1/3 of the total treatment time compared to the conventional fractionation drastically reduces the fatigue of the patients, the waiting list of each Department, as well as the cost of the treatment.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Nanos, Christos
- Νάνος, Χρήστος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51818